Highlights

  • Abingdon Health signs a USD 2m Master Service Agreement for multiplex test development.
  • Project covers feasibility, optimisation, scale-up, and technical transfer over 24 months.
  • Work to be executed from Madison, Wisconsin, leveraging dual-site CDMO capabilities.

Abingdon Health plc (LSE:ABDX) has secured a new contract with an expected value of approximately USD 2m. The agreement, structured as a Master Service Agreement (MSA) with a US-based company, covers the development, scale-up, and technical transfer of a semi-quantitative, multiplex lateral flow test system.

Scope of the Project
The MSA encompasses the full lifecycle of the project including feasibility, optimisation, scale-up, and transfer to manufacturing. Multiple work orders under the MSA are expected to total around USD 2m. The project is planned to span approximately 24 months and will be managed from Abingdon Health’s facilities in Madison, Wisconsin.

CDMO Capabilities and International Operations
The contract highlights Abingdon Health’s CDMO (Contract Development and Manufacturing Organisation) offering, which supports clients from concept through to commercial production. The expansion of the Madison manufacturing facility, accelerated after a recent GBP 3.2m net fundraise and placing, aims to meet rising demand from US-based customers.

The Group’s dual-site operations, spanning the USA and UK, allow for integrated development and regulatory support. Abingdon Health provides end-to-end CDMO services, ensuring comprehensive support across all stages of test development.

Project Significance
The semi-quantitative, multiplex lateral flow test system enables the measurement of multiple analytes in a single test, extending the utility of lateral flow testing beyond single-parameter qualitative tests. This capability allows for more detailed and informative diagnostic outputs within a compact and rapid testing format.

Operational Execution
All development, scale-up, and technical transfer activities for this contract will be carried out at the Madison facility, utilizing the Group’s technical expertise and full CDMO service platform. This approach is designed to streamline processes and ensure alignment across international operations, with support from the York, UK site.

Share Performance of ABDX

ABDX was trading 6.90% higher at 7.75 GBX per share as of 10 November 2025.